
OptiNose Investor Relations Material
Latest events

Q3 2024
OptiNose

Q1 2025
14 May, 2025

Q4 2024
26 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from OptiNose Inc
Access all reports
OptiNose Inc. is a pharmaceutical company engaged in the development and commercialization of innovative products for patients under the care of ear, nose, throat, and allergy specialists in the United States. The company has developed a proprietary Exhalation Delivery Systems, a novel drug delivery concept that facilitates broad, consistent drug delivery deep within the nasal passages. This technology aims to leverage the mucosal surfaces as a potential target for treating both local and systemic diseases. OptiNose's portfolio includes XHANCE, a therapeutic product utilizing EDS to deliver a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. Additionally, the company has developed Onzetra Xsail, a powder EDS device, and is exploring further applications of its technology in various clinical trials. OptiNose is headquartered in Yardley, Pennsylvania, and its shares are listed on the NASDAQ.
Key slides for OptiNose Inc


Q2 2024
OptiNose Inc


Q3 2024
OptiNose Inc
Latest articles
)
Nintendo: From Game Boy and Pokémon to Switch 2 and Mario Kart
Nintendo went from card maker to cultural icon, shaping modern entertainment through hardware innovation and world-famous characters.
19 Jun 2025
)
Ron Vachris: From Forklift Driver to CEO at Costco
Ron Vachris took over as Costco CEO in 2024, following a 40-year journey from warehouse floors to the top of one of retail's most admired companies.
18 Jun 2025
)
Luca de Meo: Succeeding Pinault as the New CEO of Kering
Luca de Meo's leap from auto to luxury marks a bold new chapter as he becomes the first non-Pinault CEO to lead the Kering empire.
16 Jun 2025
Ticker symbol
OPTN
Country
🇺🇸 United States